glucose-dependent insulinotropic polypeptide analogs (Amylin Pharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameglucose-dependent insulinotropic polypeptide analogs (Amylin Pharmaceuticals)
Drug Alias NameGIP analogs (Amylin)AC-165081AC-165072
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInsulin release stimulants
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIreland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Ulster
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of UlsterAmylin Pharmaceuticals Llc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A